BioRestorative Therapies (BRTX) has been granted a Type B meeting with the U.S. Food and Drug Administration to discuss a potential accelerated Biologics License Application approval pathway for the Fast-Track-Designated BRTX-100 program for the treatment of chronic lumbar disc disease. The Type B meeting is scheduled for mid-December.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRTX:
- BioRestorative Therapies: Promising Clinical Advances and Strategic Growth Drive Buy Rating
- BioRestorative Therapies’ Earnings Call: Milestones Amid Challenges
- BioRestorative Therapies Reports Q3 2025 Financials
- BioRestorative Therapies Issues Regulation FD Disclosure
- BRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?